Japan Cervical Cancer Market Insights, Epidemiology and Market Forecasts 2016-2023 – Research and Markets

DUBLIN–(BUSINESS WIRE)–Research and Markets has announced the addition of the “Cervical
Cancer-Market Insights, Epidemiology and Market Forecast – 2023 – Japan”

drug pipelines to their offering.

The therapeutic market size of Cervical Cancer in Japan will increase at
a Compound Annual Growth Rate of 1.93% and reach up to USD 2.67 million
by 2023. The global market size for prophylaxis treatment of Cervical
Cancer is expected to grow at a CAGR of 0.71% and reach up to USD 2210.9
Million by 2023.

Cervical Cancer- Market Insights, Epidemiology and Market Forecast –
2023 – Japan Report provides marketed drugs information of Cervical
Cancer. It includes historical and forecasted epidemiology and market
size of the Cervical Cancer in Japan for 2013-2023.

Cervical Cancer needs to be focused more and more because it adversely
affects younger women. It is the fourth most common cause of death among
women. Cervical Cancer occurs due to the uncontrolled growth of healthy
cells in cervix and forms cervical lesions. It spreads to other tissues
such as vagina and uterus. Cervical Cancer is caused by inheritance of
defects or mutation in genes. Cervical cancer is also caused due to the
infection by the Human Papilloma Virus (HPV) which can infect cells on
the surface of the skin and those lining the genitals, anus, mouth and
throat, but not the blood or internal organs such as the heart or lungs.

Key Topics Covered:

  1. Introduction
  2. Cervical Cancer Disease Overview
  3. Diagnosis of Cervical Cancer
  4. Epidemiology and Patient Population of Cervical Cancer
  5. Treatment Landscape
  6. Treatment Algorithm
  7. Treatment by Stages
  8. Cervical Cancer Treatment Regimens
  9. Current Unmet Needs
  10. Cervical Cancer Emerging therapies Market Size

For more information about this drug pipelines report visit http://www.researchandmarkets.com/research/wp3s23/cervical


Research and Markets
Laura Wood, Senior Manager
E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
For GMT Office Hours Call +353-1-416-8900
Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Topics: Cervical
Cancer Drugs